![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Elisavet Moutzouri, Anastazia Kei, Moses S Elisaf & Haralampos J Milionis. (2010) Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vascular Health and Risk Management 6, pages 525-539.
Read now
Read now
Vasilios G Athyros, Konstantinos Tziomalos, Dimitri P Mikhailidis, Efstathios D Pagourelias, Anna I Kakafika, Athanasios Skaperdas, Apostolos Hatzitolios & Asterios Karagiannis. (2007) Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?. Expert Opinion on Pharmacotherapy 8:14, pages 2267-2277.
Read now
Read now
Irene F. Gazi, Stella S. Daskalopoulou, Devaki R. Nair & Dimitri P. Mikhailidis. (2007) Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Current Medical Research and Opinion 23:9, pages 2183-2192.
Read now
Read now
Irene F Gazi & Dimitri P Mikhailidis. (2006) Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview. Expert Opinion on Therapeutic Targets 10:6, pages 851-866.
Read now
Read now
Boris Hansel, Anatol Kontush, Philippe Giral, Dominique Bonnefont-Rousselot, M. John Chapman & Eric Bruckert. (2006) One third of the variability in HDL‐cholesterol level in a large dyslipidaemic population is predicted by age, sex and triglyceridaemia:The Paris La Pitié Study. Current Medical Research and Opinion 22:6, pages 1149-1160.
Read now
Read now
Stella S. Daskalopoulou & Dimitri P. Mikhailidis. (2006) Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Current Medical Research and Opinion 22:3, pages 511-528.
Read now
Read now
T. D. Filippatos, D. N. Kiortsis, E. N. Liberopoulos, M. Georgoula, D. P. Mikhailidis & M. S. Elisaf. (2005) Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Current Medical Research and Opinion 21:12, pages 1997-2006.
Read now
Read now
J. Wouter Jukema, An-Ho Liem, Peter H. J. M. Dunselman, Jos A. P. van der Sloot, Dirk J. A. Lok & Aeilko H. Zwinderman. (2005) LDL‐C/HDL‐C ratio in subjects with cardiovascular disease and a low HDL‐C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. Current Medical Research and Opinion 21:11, pages 1865-1874.
Read now
Read now
James Shepherd, John Betteridge & Luc Van Gaal. (2005) Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Current Medical Research and Opinion 21:5, pages 665-682.
Read now
Read now
Gerd Assmann. (2005) Beyond statin therapy: why we need new thinking. Current Medical Research and Opinion 21:sup6, pages S3-S8.
Read now
Read now
Vasilios G. Athyros, Dimitri P. Mikhailidis, Athanasios A. Papageorgiou, Triandafillos P. Didangelos, Emmanuel S. Ganotakis, Athanasios N. Symeonidis, Stella S. Daskalopoulou, Anna I. Kakafika & Moses Elisaf. (2004) Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Current Medical Research and Opinion 20:11, pages 1691-1701.
Read now
Read now
M. John Chapman, Gerd Assmann, Jean-Charles Fruchart, James Shepherd & Cesare Sirtori. (2004) Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C*. Current Medical Research and Opinion 20:8, pages 1253-1268.
Read now
Read now
Michael Miller, Adrian Dobs, Zhong Yuan, Wendy P. Battisti, Hannah Borisute & Joanne Palmisano. (2004) Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C. Current Medical Research and Opinion 20:7, pages 1087-1094.
Read now
Read now
J. D. Lee, J. R. Morrissey & V. Patel. (2004) Recalculation of cardiovascular risk score as a surrogate marker of change in clinical care of diabetes patients: the Alphabet POEM project (Practice Of Evidence-based Medicine). Current Medical Research and Opinion 20:5, pages 765-772.
Read now
Read now
Kohji Shirai. (2004) Obesity as the core of the metabolic syndrome and the management of coronary heart disease. Current Medical Research and Opinion 20:3, pages 295-304.
Read now
Read now
Articles from other publishers (27)
Jaeho Lee, Sohyae Lee, Jin-young Min & Kyoung-bok Min. (2021) Association between Serum Lipid Parameters and Cognitive Performance in Older Adults. Journal of Clinical Medicine 10:22, pages 5405.
Crossref
Crossref
T. A. Jacobson. (2011) ‘Trig-onometry’: non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia. International Journal of Clinical Practice 65:1, pages 82-101.
Crossref
Crossref
Gin S Malhi, Danielle Adams & Janice M Plain. (2014) Metabolic syndrome: a picture of health?. Acta Neuropsychiatrica 21:4, pages 197-199.
Crossref
Crossref
Asterios Karagiannis, Apostolos I Hatzitolios, Vasilios G Athyros, Kalliopi Deligianni, Charalambos Charalambous, Christos Papathanakis, Georgios Theodosiou, Theodoros Drakidis, Veronika Chatzikaloudi, Chysanthi Kamilali, Sotirios Matsiras, Athanasios Matziris, Christos Savopoulos, Maria Baltatzi, Jobst Rudolf, Konstantinos Tziomalos & Dimitri P Mikhailidis. (2009) Implementation of Guidelines for the Management of Arterial Hypertension. The Impulsion Study. The Open Cardiovascular Medicine Journal 3:1, pages 26-34.
Crossref
Crossref
A.I. Hatzitolios, V.G. Athyros, A. Karagiannis, C. Savopoulos, C. Charalambous, G. Kyriakidis, Th. Milidis, C. Papathanakis, A. Bitli, I. Vogiatsis, G. Ntaios, N. Katsiki, A. Symeonidis, K. Tziomalos & D.P. Mikhailidis. (2009) Implementation of strategy for the management of overt dyslipidemia: The IMPROVE-dyslipidemia study. International Journal of Cardiology 134:3, pages 322-329.
Crossref
Crossref
Alpaslan Kilicarslan, Bunyamin Yavuz, Gulay Sain Guven, Enver Atalar, Levent Sahiner, Yavuz Beyazit, Murat Kekilli, Necla Ozer, Gul Oz, Ibrahim C Haznedaroglu & Tumay Sozen. (2008) Fenofibrate improves endothelial function and decreases thrombin-activatable fibrinolysis inhibitor concentration in metabolic syndrome. Blood Coagulation & Fibrinolysis 19:4, pages 310-314.
Crossref
Crossref
Peter Collins. (2008) HDL-C in post-menopausal women: An important therapeutic target. International Journal of Cardiology 124:3, pages 275-282.
Crossref
Crossref
Stephen A. Badger, Chee V. Soong, Bernard Lee, Gillian R. Swain & Kathleen E. McGuigan. (2008) Prescribing Practice of General Practitioners in Northern Ireland for Peripheral Arterial Disease. Angiology 59:1, pages 57-63.
Crossref
Crossref
Dimitri P. Mikhailidis. 2008. Vascular Complications in Human Disease. Vascular Complications in Human Disease
179
186
.
Vasilios G. Athyros, Anna I. Kakafika, Athanasios A. Papageorgiou, Konstantinos Tziomalos, Athanasios Skaperdas, Efstathios Pagourelias, Athina Pirpasopoulou, Asterios Karagiannis & Dimitri P. Mikhailidis. (2007) Atorvastatin Decreases Triacylglycerol-Associated Risk of Vascular Events in Coronary Heart Disease Patients. Lipids 42:11, pages 999-1009.
Crossref
Crossref
Yousef Khader, Anwar Bateiha, Mohammed El-Khateeb, Abeer Al-Shaikh & Kamel Ajlouni. (2007) High prevalence of the metabolic syndrome among Northern Jordanians. Journal of Diabetes and its Complications 21:4, pages 214-219.
Crossref
Crossref
Alexander Tenenbaum, Enrique Z Fisman, Michael Motro & Yehuda Adler. (2006) Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovascular Diabetology 5:1.
Crossref
Crossref
Stuart M GrieveJean-Claude AnsquerAnthony C Keech. (2006) Micronized fenofibrate: a useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes. Future Cardiology 2:6, pages 635-646.
Crossref
Crossref
. 2006. Wiley Handbook of Current and Emerging Drug Therapies. Wiley Handbook of Current and Emerging Drug Therapies.
. 2006. Wiley Handbook of Current and Emerging Drug Therapies. Wiley Handbook of Current and Emerging Drug Therapies.
. 2006. Wiley Handbook of Current and Emerging Drug Therapies. Wiley Handbook of Current and Emerging Drug Therapies.
Jonathan M. Meyer, Henry A. Nasrallah, Joseph P. McEvoy, Donald C. Goff, Sonia M. Davis, Miranda Chakos, Jayendra K. Patel, Richard S.E. Keefe, T. Scott Stroup & Jeffrey A. Lieberman. (2005) The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research 80:1, pages 9-18.
Crossref
Crossref
Joseph P. McEvoy, Jonathan M. Meyer, Donald C. Goff, Henry A. Nasrallah, Sonia M. Davis, Lisa Sullivan, Herbert Y. Meltzer, John Hsiao, T. Scott Stroup & Jeffrey A. Lieberman. (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research 80:1, pages 19-32.
Crossref
Crossref
Ian S. Young. (2016) Lipids for Psychiatrists - an overview. Journal of Psychopharmacology 19:6_suppl, pages 66-75.
Crossref
Crossref
E. N. Liberopoulos, D. P. Mikhailidis & M. S. Elisaf. (2005) Diagnosis and management of the metabolic syndrome in obesity. Obesity Reviews 6:4, pages 283-296.
Crossref
Crossref
Prediman K. Shah & Kuang-Yuh Chyu. (2005) Apolipoprotein A-I Mimetic Peptides: Potential Role in Atherosclerosis Management. Trends in Cardiovascular Medicine 15:8, pages 291-296.
Crossref
Crossref
Alberto Corsini, Stefano Bellosta & Michael H. Davidson. (2005) Pharmacokinetic Interactions Between Statins and Fibrates. The American Journal of Cardiology 96:9, pages 44-49.
Crossref
Crossref
Guntram Schernthaner. (2005) Is dyslipidaemia important if we control glycaemia?. Atherosclerosis Supplements 6:3, pages 3-10.
Crossref
Crossref
M. Taboada Taboada & A. Val Jiménez. (2005) Fármacos hipolipemiantes en prevención cardiovascular primaria y secundaria. Atención Primaria 36, pages 40-46.
Crossref
Crossref
Fahed Youssef, Prakash Gupta, Dimitri P. Mikhailidis & George Hamilton. (2016) Risk Modification in Patients with Peripheral Arterial Disease: A Retrospective Survey. Angiology 56:3, pages 279-287.
Crossref
Crossref
Philip Barter. (2016) Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: an Asian/Pacific consensus. The British Journal of Diabetes & Vascular Disease 5:2_suppl, pages S1-S15.
Crossref
Crossref
S. S. Daskalopoulou, D. P. Mikhailidis & M. Elisaf. (2016) Prevention and Treatment of the Metabolic Syndrome. Angiology 55:6, pages 589-612.
Crossref
Crossref